Product Images Enhertu

The text seems to be a list of terms, specifically describing a drug called Deruxtecan. It is a topoisomerase I inhibitor, and it appears to have a certain concentration of 8 molecules of Deruxtecan per mAb (however, it is unclear what "mAb" stands for). A linker may also be involved in the drug's composition.*

This appears to be a graph or table with numerical values plotted on two axes. The horizontal axis represents time (in months) and the vertical axis shows a progression-free survival rate (%) for two different treatments: ENHERTU and Ado-trastuzumab emtansine. Each line on the graph corresponds to a different time point (0-32 months) and shows the percentage of patients who have not progressed on each treatment at that time point. There are also numbers at risk listed for each time point, indicating the number of patients still receiving the treatment and being monitored for progression-free survival.*

ENHERTU is a medication sold in single-dose vials for intravenous infusion only. It is used in the treatment of cancer and contains fam-trastuzumab deruxtecan-nxki (100mg per vial). The medication guide is enclosed and must be dispensed to each patient. Reconstitution and dilution are necessary before administration, and unused portions should be discarded. ENHERTU is hazardous and must be stored refrigerated between 36°F to 46°F. The reconstituted solution should also be kept refrigerated up to 24 hours after reconstitution and protected from light. Each vial contains fam-trastuzumab denuxtecan-ncki, L-histidine, listdine hydrochloride monohydrate, polysorbate 80, and sucrose. Daiichi Sankyo Company produces ENHERTU in Japan. ENHERTU is a registered trademark of Daiichi Sankyo Company.*